Tsuji K - Search Results

1

Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Matono T, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Tada T, et al. Among authors: tsuji k. J Gastroenterol Hepatol. 2023 Aug;38(8):1389-1397. doi: 10.1111/jgh.16225. Epub 2023 May 25. J Gastroenterol Hepatol. 2023. PMID: 37231943

2

Endoscopic thermal ablation therapies for hepatocellular carcinoma: a multi-center study.

Sakaguchi H, Seki S, Tsuji K, Teramoto K, Suzuki M, Kioka K, Isoda N, Ido K; Japan Society for Laparoscopic Therapy Research. Sakaguchi H, et al. Among authors: tsuji k. Hepatol Res. 2009 Jan;39(1):47-52. doi: 10.1111/j.1872-034X.2008.00410.x. Epub 2008 Aug 28. Hepatol Res. 2009. PMID: 18761680

3

Efficacy and long-term outcomes of radiofrequency ablation in the elderly with hepatocellular carcinoma.

Yamazaki H, Tsuji K, Nagai K, Tomonari A, Matsui T, Kang JH, Kodama Y, Sakurai Y, Maguchi H. Yamazaki H, et al. Among authors: tsuji k. Hepatol Res. 2014 Oct;44(11):1095-101. doi: 10.1111/hepr.12233. Epub 2013 Oct 25. Hepatol Res. 2014. PMID: 24033930

4

Is there a survival benefit in interventional radiology for hepatocellular carcinoma in patients with Child-Pugh C liver cirrhosis?: A multicenter study.

Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ishikawa T, Itobayashi E, Shimada N, Takaguchi K, Takizawa D, Tsuji K; Hiroaki Nagamatsu, on behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group. Hiraoka A, et al. Among authors: tsuji k. Hepatol Res. 2016 May;46(6):521-8. doi: 10.1111/hepr.12583. Epub 2015 Oct 2. Hepatol Res. 2016. PMID: 26331402

5

Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan.

Toyoda H, Tada T, Tsuji K, Hiraoka A, Tachi Y, Itobayashi E, Takaguchi K, Senoh T, Takizawa D, Ishikawa T, Kumada T. Toyoda H, et al. Among authors: tsuji k. Hepatol Res. 2016 Jul;46(8):734-42. doi: 10.1111/hepr.12613. Epub 2015 Nov 19. Hepatol Res. 2016. PMID: 26508201

6

Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.

Toyoda H, Kumada T, Tada T, Takaguchi K, Ishikawa T, Tsuji K, Zeniya M, Iio E, Tanaka Y. Toyoda H, et al. Among authors: tsuji k. J Gastroenterol. 2016 Jul;51(7):741-7. doi: 10.1007/s00535-016-1174-4. Epub 2016 Feb 12. J Gastroenterol. 2016. PMID: 26872889 Clinical Trial.

7

Erratum to: Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.

Toyoda H, Kumada T, Tada T, Takaguchi K, Ishikawa T, Tsuji K, Zeniya M, Iio E, Tanaka Y. Toyoda H, et al. Among authors: tsuji k. J Gastroenterol. 2016 Jul;51(7):750. doi: 10.1007/s00535-016-1192-2. J Gastroenterol. 2016. PMID: 26948482 No abstract available.

8

Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.

Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Tanaka J. Tada T, et al. Among authors: tsuji k. J Gastroenterol Hepatol. 2017 Feb;32(2):451-458. doi: 10.1111/jgh.13473. J Gastroenterol Hepatol. 2017. PMID: 27288655

9

Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade.

Hiraoka A, Kumada T, Nouso K, Tsuji K, Itobayashi E, Hirooka M, Kariyama K, Ishikawa T, Tada T, Toyoda H, Kawasaki H, Hiasa Y, Michitaka K. Hiraoka A, et al. Among authors: tsuji k. Oncology. 2016;91(3):153-61. doi: 10.1159/000447061. Epub 2016 Jul 1. Oncology. 2016. PMID: 27362669

10

Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B.

Toyoda H, Kumada T, Tada T, Shimada N, Takaguchi K, Senoh T, Tsuji K, Tachi Y, Hiraoka A, Ishikawa T, Shima T, Okanoue T. Toyoda H, et al. Among authors: tsuji k. J Hepatol. 2017 Mar;66(3):521-527. doi: 10.1016/j.jhep.2016.11.012. Epub 2016 Nov 25. J Hepatol. 2017. PMID: 27890790 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,231 results

Search Page